<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563521</url>
  </required_header>
  <id_info>
    <org_study_id>astimsitokin</org_study_id>
    <nct_id>NCT03563521</nct_id>
  </id_info>
  <brief_title>Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma</brief_title>
  <official_title>Serum Cytokine Profiles of Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine and compare serum cytokine levels of six different
      severe asthma inflammatory phenotypes differentiated by their atopy, peripheral eosinophilia
      and/or chronic rhinosinusitis and/or nasal polyposis status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective observational study of 90 adults diagnosed with severe asthma and on regular
      follow-up and 15 control subjects will be investigated. Stable (controlled or
      partly-controlled) status (of all) and exacerbated-status (if any) serum cytokine levels
      [IL-4, IL-5, IL-10, IL-13, IL-25, IL-33, thymic stromal lymphopoietin (TSLP), IL-17A,
      periostin) will be evaluated. Also nasopharyngeal brush samples will be obtained for
      respiratory tract panel work-up with PCR in exacerbated patients. Effect of viral infections'
      on cytokine response in different inflammatory phenotypes will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Serum cytokine levels</measure>
    <time_frame>10 months</time_frame>
    <description>Measurement of stable state and exacerbation state levels of serum cytokines (IL-4, IL-5, IL10, IL-13, IL-17, IL-25, IL-33, TSLP, periostin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal brush sample PCR</measure>
    <time_frame>10 months</time_frame>
    <description>Detecting pharyngeal pathogens with PCR taken during exacerbated state</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">95</enrollment>
  <condition>Asthma Persistent</condition>
  <condition>Asthma, Allergic</condition>
  <condition>Eosinophilic Asthma</condition>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Atopic, eosinophilic</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic, non-eosinophilic</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-atopic, eosinophilic</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic rhinosinusitis with/without nasal polyposis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-atopic, non-eosinophilic</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Without asthma, atopy and eosinophilia</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum nasopharyngeal brush (to detect pharyngeal tract pathogens with PCR)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Asthmatic groups will be selected from the Erciyes University Allergy Clinic admisisons.

        Control group wil be selected from the Erciyes University Allergy Clinic admisisons and
        from the volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (for disease groups):

          1. Patients diagnosed with severe asthma and followed-up at least 6 months at our clinic

          2. Asthma that can only be complete or partly controlled with Global Initiative for
             Asthma (GINA) 4-5 treatment

          3. Asthmatics that are eligible for the defined phenotypes

          4. At least one perennial allergen sensitivity for the atopic groups

        Inclusion Criteria (for control group):

          1. Non-asthmatics (without clinical and pulmonary function test evidence)

          2. Non-atopics (proved by skin prick tests)

          3. Serum eosinophil count &lt;300/cells

        Exclusion Criteria (for disease groups):

          1. &lt;18 year-old

          2. Smoking history within the last 1 year prior to the study

          3. Asthmatics with inadequate inhaler technique and/or adherence problems

          4. Comorbidities: malignancy history, connective tissue disorders, rheumatological
             disorders, hyperthyroidism, coronary heart diseases, diabetes mellitus, active hepatic
             diseases, akut kidney injury, any autoimmune diseases

          5. Organ transplantation history

          6. Pregnancy

          7. Other pulmonary problems: chronic obstructive pulmonary disease (COPD),
             bronchiectasis, interstitial lung diseases, pulmonary thromboemboli

          8. During stable period investigation

               1. Asthma control test &lt;20

               2. Upper respiratory tract infections within 1 month before admission

               3. Exacerbation and/or systemic steroid use within 1 month before admission

          9. Atopic patients that only have seasonal allergen sensitivity

        Inclusion Criteria (for control group):

          1. &lt;18 year-old

          2. Smoking history within the last 1 year prior to the study

          3. Asthmatics with inadequate inhaler technique and/or adherence problems

          4. Comorbidities: malignancy history, connective tissue disorders, rheumatological
             disorders, hyperthyroidism, coronary heart diseases, diabetes mellitus, active hepatic
             diseases, akut kidney injury, any autoimmune diseases

          5. Organ transplantation history

          6. Pregnancy

          7. Other pulmonary problems: COPD, bronchiectasis, interstitial lung diseases, pulmonary
             thromboemboli

          8. Without consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erciyes University School of Medicine Division of Allergy</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Murat TÃ¼rk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>inflammatory phenotypes</keyword>
  <keyword>serum cytokines</keyword>
  <keyword>eosinophilia</keyword>
  <keyword>atopy</keyword>
  <keyword>chronic rhinosinusitis with nasal polyposis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

